Ixekizumab patent expiry uk?

When does the ixekizumab patent expire in the UK?

There isn’t enough information provided here to determine a specific ixekizumab (Taltz) patent expiry date for the UK. Patent expiry depends on which protection(s) you mean (primary patent term vs. any Supplementary Protection Certificate (SPC)), and the exact dates can vary by patent family and jurisdiction.

If you want, share either (a) the UK patent number(s) / SPC number(s) you’re looking at, or (b) the patent/family name you found (from Google Patents, Espacenet, UKIPO, or a drug-patent database). Then the expiry can be pinned down precisely.

Are there UK SPCs (and do they extend expiry)?

In the UK, biologic medicines like ixekizumab often have multiple layers of protection. Even when a primary patent term is close to expiry, an SPC can extend exclusivity, and there can also be earlier expiry for some claims or jurisdictions within the same family.

To confirm whether an SPC exists for ixekizumab in the UK and what it covers, you would typically check:
- the UK SPC register for ixekizumab,
- the underlying UK/EP patent(s) linked to that SPC,
- and any later changes (for example, claim adjustments or related litigation outcomes).

How can I check the exact UK expiry date myself (fast)?

You can usually get the right answer quickly by locating the “UK patent/SPC” records for ixekizumab and then reading the “expiry” field for the relevant instrument. Practical sources include:
- UKIPO (for patents and related record links),
- the UK SPC register (to see whether a supplementary protection certificate exists),
- and Espacenet/Google Patents (to identify the exact UK filing/patent number first, then cross-check).

Does “patent expiry” equal loss of market exclusivity in the UK?

Not always. Even after a particular patent or SPC expiry date, you may still see delays in generic or biosimilar entry due to:
- other still-in-force patents covering different aspects (formulations, methods, dosing regimens, mechanisms),
- regulatory exclusivity rules,
- and litigation that can delay approvals or launch timing.

So the “last” date that matters for biosimilar entry is often the expiry of the final relevant protection, not the first one to lapse.

What if you meant “biosimilar entry date” instead of patent expiry?

If your real goal is “when will a biosimilar be able to launch in the UK,” the timeline can be later or earlier than a single patent’s expiry date, depending on:
- whether multiple patents/SPCs remain in force,
- how UK court decisions affect enforceability,
- and what the UK regulator allows at that point.

To answer that precisely, the same missing detail applies: which specific UK patents/SPCs you want to track.

Which details should you provide for a precise UK expiry answer?

Send any one of the following and the expiry date can be identified accurately:
- a UK patent number for ixekizumab,
- an SPC number (UK),
- a link to the UK/EP record you’re using,
- or the patent family identifier (so the correct family’s UK instruments can be matched).

Sources

No sources were provided in the prompt, so I can’t cite specific UK ixekizumab patent/SPC expiry dates.